*Temporary enrollment pause due to coronavirus (COVID-19)*

Please note that study site locations for this study may not be accepting new study participants at this time in light of the situation with the coronavirus (COVID-19). Please check back at a later date as we expect to continue recruitment/enrollment in the future as this situation changes.

Who is eligible to participate?

The DISCREET Study may be an option for those who meet the following criteria:

  • Are 18 years of age or older
  • Have been diagnosed with chronic plaque psoriasis for at least six months, and have moderate to severe psoriasis of the genital area
  • Are intolerant to topical therapy, or have been treated with topical therapy for psoriasis affecting the genital area but the psoriasis was inadequately controlled

If you meet these initial criteria, we invite you to take the prescreening questionnaire below to see if you may qualify to participate in this study.

More about study participation

Participation in the DISCREET Study lasts approximately 41 weeks, including:
  • A screening phase of up to 35 days (five weeks)
  • A double-blind placebo-controlled phase that will last 16 weeks
  • An additional 16 weeks for the study drug extension phase
  • A four-week post-treatment observational follow-up phase